GentiBio

Cell & Gene Therapy · Health Care
Sponsors visas
Lately:1 news story in 90 daysFollow changes →

Facts

as of Nov 17, 2026

Our modular engineering platform allows us to create optimized Tregs phenotypes tailored to address a wide variety of autoimmune, alloimmune and inflammatory diseases.

Headquarters
Cambridge, United States
Official records
Wikidata Q140876913
Website
gentibio.com

These are the key facts about GentiBio on Alion as of Nov 17, 2026. GentiBio is headquartered in Cambridge, United States. The latest round is Series A of $157M, announced in 2021.

Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake

What the registers and the postings say about this employer.

Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices

Named in the work visa registers of United States.

United StatesUS 1 #5,756 of 8,997 sponsors
1H-1B filings in 12 months
$168kMedian offered salary
0Open roles in United States
Who they sponsor
Other biological scientists1
The salary offered for each occupationVisa pass · 90 credits

In the register as GentiBio, Inc., Cambridge, MA

Other sponsors in the same field
Alert me
US Department of Labor · latest filing Feb 24, 2026

Footprint

Hiring in 1 city in 1 country.

1Cities
1Countries
SiteTypeOpen rolesHires most forEngineering
Cambridge United StatesHeadquarters0
Source: office addresses in postings and company registers

Financials

Funding rounds, investors and revenue on record.

$157MTotal raised
$1.2MPublic grants1 public grant
GrantLatest round
2Rounds and grants
Money by yearUSD, rounds and grants
2025$1.2M1 record
2021$157M1 record
Largest rounds and grants
$157M
2025
$1.2M
Sources: funding announcements, grant and company registers

Milestones

Aug 15, 2025
Won a grant $1.2M · CORDIS
Aug 10, 2021
Raised a round Series A $157M
Sep 2020
Each milestone is dated by its source: registers, filings, the press

Newsroom

Sep 252026
News · pharmaphorum
Bristol-Myers Squibb has formed an R&D partnership with GentiBio, aimed at developing regulatory T cel (Treg) therapies for inflammatory bowel disease (IBD). The deal includes an…
Mar 182026
Press release · PRNewswire
/PRNewswire/ -- GentiBio, Inc., a clinical-stage biotechnology company pioneering engineered, antigen-specific regulatory T cell (EngTreg) therapies, today...
Sources: the outlets named on each headline, each story once